这是让全民感染自动免疫的做法。
亦即生死由命。
安省的做法也和BC无异。
全加拿大民众自求多福吧!
亦即生死由命。
安省的做法也和BC无异。
全加拿大民众自求多福吧!
怕没那么简单吧。真实官僚主义
这是准备全民感染的节奏无意中在网上看到一网友评论BC省的世界级抗新冠疫情:只给有限人群反复检测,家庭医生,网上医生,急诊科医生确定是新冠也不给检测,说试剂盒不够。UBC专家说可以提供2 millions检测剂,Dr. Henry 又说等曲线压平了再给检测。国际康复标准是在一定时间内连续三次检测为阴性才可以确定康复. 这边居然没症状就算康复。看看这些数字,死亡率2%,治愈率31%.看看世界上那个国家有如此高的治愈率?有特效药吗?没有,全靠自免疫力。
上面评论说的信息还不能确定是否都属实(比如说UBC专家说可以提供2 millions检测剂等),但是引起我的兴趣来对比中加(严格来说是BC省)新冠肺炎病人康复标准,哪个更可靠谱?通过网上搜刮来的资料,简单对比如下:
1.中国新冠肺炎病人康复标准:
据国家卫生健康委体改司司长梁万年介绍,中国新冠肺炎病人的标准是新冠肺炎患者在临床症状消失、体征恢复后,间隔24小时进行两次核酸检测,若结果为双阴才可出院。为防止出院后出现复阳,出院病人需接受14天医学观察。在做完进一步测试后(第三次核酸检测),才能说病人是否康复。
2.BC省新冠肺炎病人康复标准:
轻症新冠患者应在自我隔离10-15天后,患者呼吸道症状消失(不计算咳嗽),体温正常就算康复了,可以进行正常日常活动了。简单粗暴吧!附BCCDC原文如下:
With or without a history of travel, if you have respiratory symptoms that can be managed at home, self-isolate at home for at least 10 days after onset of symptoms. After 10 days, if your temperature is normal and you feel better, you can return to your routine activities. Coughing may persist for several weeks, so a cough alone does not mean you need to continue to self-isolate for more than 10 days.
Here are two examples of differing self-isolation periods for returning travellers that develop respiratory symptoms upon their return:
Example 1: Respiratory symptoms appear five days after returning to Canada. Self-isolate for 10 additional days for a total of 15 days.
Example 2: Respiratory symptoms appear two days after returning to Canada. Self-isolate for 10 additional days for a total of 12 days.
最后说一下BC省新冠病毒检测标准,因为这个和新冠肺炎病人康复标准有关联。目前BC的检测标准是优先测重症病人,和出现症状的医护人员,养老院的老人,重慢性病人。其他轻症的基本不测居家自我隔离。BC省卫生官员邦妮·亨利(Bonnie Henry)博士表示,对民众进行广泛测试,只有当疫情曲线出现下降后才会进行(为什么??)
因为居家自我隔离的轻症患者不测,所以14天隔离期过后如果没有变危重自然也是不测的,这一类轻症患者“被康复“后还会不会继续传播新冠病毒应该也是不确定的,到底对社区工作环境造成多大危险也是个未知数,是不是BC的童鞋们只能靠自我保护自求多福了?
今天星期六(3月28号)一大早,刚刚结束隔离期的加拿大总理特鲁多(Justin Trudeau)宣布,任何出现新冠病毒症状的民众,都禁止乘坐加拿大境内的飞机或火车,以减缓病毒在加拿大传播。
这个限制措施于周一中午生效,适用于任何显示出新冠病毒迹象的人,包括咳嗽、发烧和呼吸困难。
出现上述症状的旅行者将不能够在加拿大任何地方的省市之间乘坐飞机或火车旅行。
特鲁多于今天早上发表对加拿大人的每日讲话中表示:“航空公司和火车的运营商要确保表现出症状的人不要登上这些火车至关重要。” “这是加拿大交通部的一项规定,与此同时,如果旅行不是绝对必要的话,请留在家里。”
总理补充指,联邦政府将为航空公司和铁路公司提供“更多工具”,以阻止那些表现出症状的人乘坐飞机和火车,但目前没有提供这些增强筛查措施的详情。
不过,特鲁多表示,该禁令不适用于省际巴士旅行,因为该旅行不受联邦政府管辖。
---你们看看,要说政府部门头头大多不知道轻症状不测的人群对社会的潜在传播病毒的危害性,我也是不太相信的,是因为检测工具不足不得已而为之?
看到谭书记这面孔就觉得讨厌,很多国家包括加拿大都被误导有些甚至被带进沟里,最终导致新冠世界大流行,谭书记功不可没。。。世卫组织刚修改规则:冠状病毒被证实气溶胶传播!在空气中可存活8个小时
世卫组织刚刚修改规则:冠状病毒被证实气溶胶传播,在空气中可存活8个小时。所以,要求每个人任何地方都得戴口罩。
爆炸性的消息:
冠状病毒被证实通过空气传播!!!
冠状病毒能在铜和钢等金属表面存活2个小时。
能在纸和塑料上存活3-4小时。
在空气中可根据具体情况存活8小时甚至更长时间。
世卫组织更正了他们早期认为冠状病毒不会空气传播的观点。
请大家不要去有空调的公共场所,尤其不要去小而密闭的房间。
这是从中国封城以来,有关这场瘟疫最有价值的消息(美国的快速度病毒检测仪)!!!!!!
一天生产五万台测试机 不靠谱
可以做五万测试 还差不多
33楼里面一天生产五万台测试机是曝光乐视老板美国资产的顾秀竞博士文章说的,我没有时间考证消息来源,应该也很容易查到的。FDA已经通过并授权!
可以想见,额温枪是基本工具之一,其它的都不好整。。。这个政策怎么实施呢?
我看还是中国的测温枪简单实用
西方国家绕了一大圈
最后还是得回到中国标准
我看一篇文章说现在一天可做五万测试
没说一天可生产五万台测试机
测试次数和测试机台数 差别挺大的
听听就好了,别认真。美国人还高调说捐赠中国一亿美金呐,到后来,不吱声了。
好贴 赞俺吃过早饭查了一下,新测试机五分钟可以测出阳性结果是真的,但是确实没说得很清楚是一天可生产五万台测试机还是测试机一天可做五万测试(我个人倾向于后者),产生歧义应该是下面这句话:
The company will ramp up its production to make 50,000 units per day beginning next week.
附全文大家看看如下:
The FDA has approved emergency use of a new coronavirus test that delivers positive results in 5 minutes and negative results in 13
Abbott Laboratories announced Friday that the FDA approved the emergency use of its new Abbott ID NOW COVID-19 test, which can deliver positive test results for the novel coronavirus in five minutes and negative results in 13.
The test — which is the size of a small toaster — is compact enough that it can be used in any health care setting, including a physician's office or urgent care clinics.
The company will ramp up its production to make 50,000 units per day beginning next week.
The US Food and Drug Administration granted Emergency Use Authorization (EUA) to a COVID-19 test that delivers positive results in five minutes and negative results in 13 minutes.
Abbott Laboratories claims its ID NOW COVID-19 test could dramatically change the battle against the novel coronavirus in the US. The test runs on Abbott's ID NOW platform, which is the most common point-of-care test in the US. It is also used to test other viruses including Influenza A&B, Strep A and respiratory syncytial virus (RSV) testing.
The medical device is small and compact enough that it can be used in nearly any healthcare setting, expanding the number of places it can be used to detect the novel virus. The medical device, which is about the size of a toaster, is portable and can be set up anywhere, from a physician's office to an urgent care clinic, the company boasted in a press release.
"Abbott's ID NOW COVID-19 test will help battle the pandemic in real-time by bringing vital information in minutes to frontline clinicians who are working to stop the spread of the virus," John Frels, vice president of research and development at Abbott Diagnostics, told Business Insider.
After Abbott Laboratories received approval from the FDA for its ID NOW COVID-19 test on Friday, the medical device company announced that it would be ramping up its production to make 50,000 units per day as early as next week. According to a spokesperson from Abbott, the tests will be available beginning on April 1.
The FDA also approved Abbott's m2000 RealTime system for coronavirus detection last week. With the two systems combined, the medical device company claims it will produce about 5 million tests for the novel virus in April.
Abbott Laboratories is working with the Trump Administration to deploy the tests to sites where they will have the most impact and will likely target hospital emergency departments, urgent-care clinics, and physicians' offices.
The Abbott ID NOW COVID-19 detects the presence of nucleic acid from SARS-CoV-2 by "identifying a small section of the virus' genome, then amplifying that portion until there's enough for detection."
The molecular testing technology delivers COVID-19 results in minutes. Other coronavirus testing methods require health workers to take samples from possible coronavirus patients to be delivered to testing labs, taking hours or even days to get results.
However, Abbott n0ted that ID NOW COVID-19 EUA is not FDA cleared or approved, meaning it can only be used by authorized laboratories and patient care settings.
According to Abbott Laboratories, its ID NOW COVID-19 test is the fastest available molecular point-of-care test. However, other companies producing medical devices with even faster testing capabilities are racing to receive approval from the FDA. Henry Schein Inc. is developing a point-of-care antibody test, however, it cannot definitely diagnose an infection, Bloomberg reported.
The US government has been criticized for its lagging response to the coronavirus, including its low testing capabilities after weeks and delays in producing its own coronavirus test. However, the testing capabilities in the US are finally beginning to catch up, resulting in a surge of confirmed cases across the country going from 32,000 on March 22 to over 100,000 today.
While the US testing capabilities are now in a better place, the healthcare system still faces extreme shortages of critical medical supplies to treat COVID-19 patients, including ventilators and personal protective gear for health workers, including masks.
确实是自求多福了,这是一个新事物,BC的做法对不对,目前没人知道,也许他们说的治愈就真没有传染性了,也许真就拦下大暴发也不一定。但大疫当前,国人的思维是宁可防疫过当,也不可防疫不到位,所以躲着别出来,保护自己,保护家人,保护所爱,永远是正确选择!
俺吃过早饭查了一下,新测试机五分钟可以测出阳性结果是真的,但是确实没说得很清楚是一天可生产五万台测试机还是测试机一天可做五万测试(我个人倾向于后者),产生歧义应该是下面这句话:
The company will ramp up its production to make 50,000 units per day beginning next week.
附全文大家看看如下:
The FDA has approved emergency use of a new coronavirus test that delivers positive results in 5 minutes and negative results in 13
Abbott Laboratories announced Friday that the FDA approved the emergency use of its new Abbott ID NOW COVID-19 test, which can deliver positive test results for the novel coronavirus in five minutes and negative results in 13.
The test — which is the size of a small toaster — is compact enough that it can be used in any health care setting, including a physician's office or urgent care clinics.
The company will ramp up its production to make 50,000 units per day beginning next week.
The US Food and Drug Administration granted Emergency Use Authorization (EUA) to a COVID-19 test that delivers positive results in five minutes and negative results in 13 minutes.
Abbott Laboratories claims its ID NOW COVID-19 test could dramatically change the battle against the novel coronavirus in the US. The test runs on Abbott's ID NOW platform, which is the most common point-of-care test in the US. It is also used to test other viruses including Influenza A&B, Strep A and respiratory syncytial virus (RSV) testing.
The medical device is small and compact enough that it can be used in nearly any healthcare setting, expanding the number of places it can be used to detect the novel virus. The medical device, which is about the size of a toaster, is portable and can be set up anywhere, from a physician's office to an urgent care clinic, the company boasted in a press release.
"Abbott's ID NOW COVID-19 test will help battle the pandemic in real-time by bringing vital information in minutes to frontline clinicians who are working to stop the spread of the virus," John Frels, vice president of research and development at Abbott Diagnostics, told Business Insider.
After Abbott Laboratories received approval from the FDA for its ID NOW COVID-19 test on Friday, the medical device company announced that it would be ramping up its production to make 50,000 units per day as early as next week. According to a spokesperson from Abbott, the tests will be available beginning on April 1.
The FDA also approved Abbott's m2000 RealTime system for coronavirus detection last week. With the two systems combined, the medical device company claims it will produce about 5 million tests for the novel virus in April.
Abbott Laboratories is working with the Trump Administration to deploy the tests to sites where they will have the most impact and will likely target hospital emergency departments, urgent-care clinics, and physicians' offices.
The Abbott ID NOW COVID-19 detects the presence of nucleic acid from SARS-CoV-2 by "identifying a small section of the virus' genome, then amplifying that portion until there's enough for detection."
The molecular testing technology delivers COVID-19 results in minutes. Other coronavirus testing methods require health workers to take samples from possible coronavirus patients to be delivered to testing labs, taking hours or even days to get results.
However, Abbott n0ted that ID NOW COVID-19 EUA is not FDA cleared or approved, meaning it can only be used by authorized laboratories and patient care settings.
According to Abbott Laboratories, its ID NOW COVID-19 test is the fastest available molecular point-of-care test. However, other companies producing medical devices with even faster testing capabilities are racing to receive approval from the FDA. Henry Schein Inc. is developing a point-of-care antibody test, however, it cannot definitely diagnose an infection, Bloomberg reported.
The US government has been criticized for its lagging response to the coronavirus, including its low testing capabilities after weeks and delays in producing its own coronavirus test. However, the testing capabilities in the US are finally beginning to catch up, resulting in a surge of confirmed cases across the country going from 32,000 on March 22 to over 100,000 today.
While the US testing capabilities are now in a better place, the healthcare system still faces extreme shortages of critical medical supplies to treat COVID-19 patients, including ventilators and personal protective gear for health workers, including masks.